Unique ID issued by UMIN | UMIN000004223 |
---|---|
Receipt number | R000005074 |
Scientific Title | Feasibility study of Neoadjuvant chemoradiotherapy for locally advanced esophageal carcinoma |
Date of disclosure of the study information | 2010/09/16 |
Last modified on | 2018/10/31 22:37:13 |
Feasibility study of Neoadjuvant chemoradiotherapy for locally advanced esophageal carcinoma
NeoCRT trial
Feasibility study of Neoadjuvant chemoradiotherapy for locally advanced esophageal carcinoma
NeoCRT trial
Japan |
Esophageal Cancer
Gastroenterology | Gastrointestinal surgery | Radiology |
Malignancy
NO
To evaluate the feasibility of neoadjuvant chemoradiotherapy with 5-FU and CDDP for resectable locally advanced esophageal cancer
Safety,Efficacy
Phase II
Completion proportion of curative surgery
Overall survival, Progression free survival, curative resection rate,
Response rate for CRT
Pathological CR rate
Acute toxicity
Late toxicity
Surgical toxicity
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine |
Chemoradiotherapy(5-FU+CDDP+RT)
Surgery
20 | years-old | <= |
75 | years-old | >= |
Male and Female
1)Historically proven squamous cell or adeon-squamous cell carcinoma.
2)Thoracic esophageal cancer
3)Clinical T2-3N0M0 or T1-3N1M0 (UICC6th)
4)Age more than 20years and less than 75 years.
5)ECOG performance status of 0,1 or 2.
6)Patients who had any evaluable lesion.
7)No prior therapy for esophageal cancer except curative endoscopic therapy.
8)No prior chemotherapy or radiotherapy for other cancr.
9)No palsy of recurrent nerve
10)Required baseline laboratory parameters (within 7 days before registration):
Hb more than 10.0g/dl
Neutrophil more than 2000/ul
Plt more than 100,000/ul
T-Bil less than 1.5mg/dl
GOT less than 100 IU/l
GPT less than 100 IU/l
Ccr more than 60mg/min
11)The patients who were considered to be undergone transthoracic esophagectomy with D2 lymphonode dissection.
12)Signed informed consent of the patient for the registration.
1)active other malignancies within 5 years
2)Pregnant or lactating women, women who are capable of pregnancy or intend to get pregnant, men who don't intend to have protected intercourse.
3)Unsuitable mental status and condition for clinical trials.
4)Patients who received ontinuous steroids (orally or intravenous) administration.
5)Positive HBsAg.
6)Unstable diabetes mellitus with oral hypoglycemic agent or insulin.
7)Acute myocardial infarction within 3 months
8)severe complications (COPD, interstitial lung disease, pulmonary fibrosis, heart failure and so on)
9)clinically significant infectious disease(body temperature less than 38.0 degrees)
10)Any other cases who are regarded as inadequate for study enrollment by the investigator.
60
1st name | |
Middle name | |
Last name | Ken Kato |
National Cancer Center Hospital
Gastrointestinal Oncology Division
5-1-1 Tsukiji Chuo-ku Tokyo
03-3542-2511
kenkato@ncc.go.jp
1st name | |
Middle name | |
Last name | Jun Hashimoto |
National Cancer Center Hospital
Gastrointestinal Oncology Division
5-1-1 Tsukiji Chuo-ku Tokyo
03-3542-2511
kenkato@ncc.go.jp
National Cancer Center Hospital
Ministry of Health, Labor and Welfare
Japanese Governmental office
Japan
NO
国立がん研究センター中央病院(東京都)
国立がん研究センター東病院(千葉県)
栃木県立がんセンター(栃木県)
静岡県立静岡がんセンター(静岡県)
千葉大学医学部(千葉県)
2010 | Year | 09 | Month | 16 | Day |
Published
Completed
2010 | Year | 03 | Month | 08 | Day |
2010 | Year | 07 | Month | 01 | Day |
2013 | Year | 07 | Month | 01 | Day |
2013 | Year | 12 | Month | 01 | Day |
2013 | Year | 12 | Month | 01 | Day |
2014 | Year | 07 | Month | 01 | Day |
2010 | Year | 09 | Month | 16 | Day |
2018 | Year | 10 | Month | 31 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005074